Topical Boswellia Serrata 2% to Prevent Radiation Dermatitis in Head and Neck Cancer
Topical Boswellia Serrata Roxb. Gum Resin 2% Cream for the Prevention of Radiation-Induced Dermatitis in Head and Neck Cancer Patients
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Background: Acute radiation-induced dermatitis is a common adverse effect in patients undergoing radiotherapy for head and neck cancer, and it can impair quality of life and, when severe, contribute to treatment interruptions. Boswellia serrata gum resin (Indian olibanum) has recognized anti-inflammatory properties, and a topical boswellic-acid cream previously reduced skin-reaction severity and the need for rescue corticosteroids in breast radiotherapy. Evidence in head and neck cancer is lacking.
Objective: To evaluate the efficacy of a 2% Boswellia serrata gum-resin topical cream in preventing or reducing acute radiation-induced dermatitis in head and neck cancer patients undergoing radiotherapy.
Design: Non-randomized (quasi-experimental), open-label, interventional study with two parallel groups. The intervention group applies the 2% Boswellia cream to the radiation field twice daily throughout radiotherapy; the control group receives no preventive topical treatment (rescue treatment only if skin reactions occur). Planned enrollment is 60 participants (about 30 per group), based on an a priori power analysis for the difference in rescue-treatment requirement between groups.
Setting: Alexandria University Main Hospitals and Ayady Almostakbal Hospital, Egypt.
Assessments: Skin toxicity is graded at baseline, weekly during radiotherapy, at the end of radiotherapy, and at 2 and 4 weeks after radiotherapy, using both the RTOG acute radiation morbidity skin score and CTCAE v5.0. Patient-reported pain, itching, and burning (numeric rating scales) and a skin-related quality-of-life instrument are collected. Rescue interventions, adverse events, and radiotherapy interruptions are logged.
Ethics: The study was approved by the Research Ethics Committee, Faculty of Medicine, Alexandria University (serial 0109668; IRB 00012098; FWA 00018699). Written informed consent is obtained from every participant before enrollment.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Youssef Hashem Hafez
- Puhelinnumero: +20 110 007 9619
- Sähköposti: youssefhashem17@gmail.com
Opiskelupaikat
-
-
-
Alexandria, Egypti
- Rekrytointi
- Alexandria university main hospitals
-
Alexandria, Egypti
- Rekrytointi
- Ayady Almostakbal Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
-
Inclusion Criteria:
- Adults aged 18 years or older, of any sex, with histologically confirmed head and neck cancer for which radiotherapy is indicated
- Planned external-beam radiotherapy to the head and neck region (curative or adjuvant intent) with a planned total dose of at least 60 Gy; concurrent chemotherapy is permitted
- Able to provide written informed consent and comply with the protocol (twice-daily cream application, follow-up visits, and a skin diary)
- Agreement to avoid other topical treatments in the radiation field during the study period (except study-provided or allowed rescue medication)
Exclusion Criteria:
- Previous radiotherapy to the same site
- Previous extensive surgery or reconstruction in the head and neck region that substantially alters the radiation field or interferes with skin assessment
- Known allergy or hypersensitivity to Boswellia serrata, boswellic acids, or any component of the cream base
- Current use of systemic corticosteroids or anti-inflammatory medications that could influence skin reactions (low-dose corticosteroids as chemotherapy premedication are allowed)
- Dermatologic conditions in the treatment area that could interfere with assessment (e.g., psoriasis, scleroderma, severe acne, chronic wounds)
- Pre-existing dermatitis or significant skin lesions in the radiation field at baseline
- Pregnancy or breastfeeding
- Any other condition that, in the investigator's judgment, would compromise participation or confound the results
Exclusion Criteria:
-
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Boswellia 2% Cream
Topical Boswellia serrata 2% gum-resin cream applied to the radiation field twice daily throughout the radiotherapy course.
|
A cream containing 2% Boswellia serrata (Indian olibanum) gum resin, applied to the radiation field twice daily throughout the radiotherapy course.
|
|
Ei väliintuloa: Control (No Preventive Treatment)
No preventive topical treatment during radiotherapy; usual care, with rescue treatment provided only if skin reactions occur.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Rescue treatment requirement
Aikaikkuna: From start of radiotherapy through 4 weeks after completion of radiotherapy (up to approximately 11 weeks)
|
Proportion of participants who require any rescue medication beyond the study cream to manage skin reactions (most importantly topical corticosteroids, but also oral analgesics, antibiotics, or wound care).
|
From start of radiotherapy through 4 weeks after completion of radiotherapy (up to approximately 11 weeks)
|
|
Improvement in skin condition (change-of-condition assessment)
Aikaikkuna: At the end of radiotherapy (approximately 7 weeks)
|
Proportion of participants whose skin condition is rated 'improved' or 'in remission' versus 'unchanged' or 'worsened' on a standardized change-of-condition assessment (adapted from psoriasis/eczema studies) at the end of radiotherapy.
|
At the end of radiotherapy (approximately 7 weeks)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to onset of radiodermatitis
Aikaikkuna: From start of radiotherapy through 4 weeks after completion (up to approximately 11 weeks)
|
Time (days) from the start of radiotherapy to the first occurrence of a grade 1 or higher skin reaction (RTOG/CTCAE).
|
From start of radiotherapy through 4 weeks after completion (up to approximately 11 weeks)
|
|
Maximum severity of radiodermatitis
Aikaikkuna: From start of radiotherapy through 4 weeks after completion (up to approximately 11 weeks)
|
Highest radiodermatitis grade recorded during the study, assessed using the RTOG acute radiation morbidity skin score and CTCAE v5.0.
|
From start of radiotherapy through 4 weeks after completion (up to approximately 11 weeks)
|
|
Patient-reported skin symptoms
Aikaikkuna: Weekly, from start of radiotherapy through 4 weeks after completion (up to approximately 11 weeks)
|
Weekly patient-reported pain, itching, and burning of the treated skin, each rated on a 0-10 numeric rating scale.
|
Weekly, from start of radiotherapy through 4 weeks after completion (up to approximately 11 weeks)
|
|
Radiotherapy interruptions due to skin toxicity
Aikaikkuna: During radiotherapy (approximately 7 weeks)
|
Number and duration (days) of radiotherapy interruptions or missed fractions attributable to skin toxicity.
|
During radiotherapy (approximately 7 weeks)
|
|
Incidence of adverse events (safety and tolerability)
Aikaikkuna: From start of radiotherapy through 4 weeks after completion (up to approximately 11 weeks)
|
Incidence of local and systemic adverse events, including allergic contact dermatitis, associated with daily application of the study cream.
|
From start of radiotherapy through 4 weeks after completion (up to approximately 11 weeks)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- BOSWELLIA-RD-HNC-2026
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .